AMR: IMI’s Enable project reaches endpoints

The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.

Read more

MercachemSyncom, Bionetix, and ProQinase ink AML contract

Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing

Read more

iOnctura SA bags €15m in Series A round

Merck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.

Read more

BioNTech acquires Neon at cheapest for $67m

mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.

Read more

New stromal target overcomes cancer resistance

British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.

Read more

Astellas and Adaptimmune team up in CAR-T development

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

Read more

Illumina embraces Roche

Twelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.

Read more

Novadiscovery takes off with €5 Series A financing

In silico clinical trials pioneer Novadiscovery SA has raised €5m in a series A financing led by Swiss Debiopharm Innovation Fund.

Read more

Alderaan Biotechnology raise €18.5m in Series A financing

Following a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi.

Read more